Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36 N.5, and our video podcast, CANCER BUZZ TV.
 

Share

    


In This Section

Home / Learn / Continuing Education Activities

Continuing Education Activities

Optimizing Advanced NSCLC Biomarker Testing, Treatment, and Management

This enduring material was recorded from an interactive, virtual (live) summit to enhance coordination of patient care and gain deeper scientific knowledge, skills, and competence in biomarker testing practices, treatment selection, and management of adverse events in patients with advanced NSCLC.

  • Session 1:  Learn what factors influence testing selection for patients with advanced NSCLC.
  • Session 2:  Gain clarity on biomarker testing methodology and recommendations.
  • Session 3:  Hear insights on advanced NSCLC treatment opportunities and optimizing patient care.

Credits Available: This activity offers up to 4.5 hours of CME/CMLE credit.
Enroll Today

 

Making Sense of the Evolving Standards of Care for Advanced HER2+ Breast Cancer

ACCC developed a series of meaningful small-group educational sessions to help clinicians optimally manage patients with HER2-positive breast cancer who have received prior treatment with anti-HER2 targeted therapies.


These interactive learning opportunities will focus on mentoring and peer-to-peer support for multidisciplinary team members. We are recruiting group leaders (3-4 hours over 8 weeks; honorarium provided) and participants (2.5 hours over 8 weeks).

Enroll as a group leader—and encourage your colleagues to join as participants. Or join an active group. Several groups need a few more participants before they can launch.

Credits Available: 1.0 AMA PRA Category 1 Credit(s)™: 1.0 contact hour of continuing pharmacy education credit; 1.0 contact hour for nurses.
Enroll Today

 

Optimizing Outcomes for Patients with Urothelial Carcinoma: Recent Clinical Updates

With the evolving treatment landscape for urothelial carcinoma, community clinicians are challenged to keep abreast with evidence-based practice guidelines, the clinical efficacy for new therapies, monitoring and managing adverse events, and engaging patients sufficiently to help them make informed treatment decisions.

This one-hour, on-demand educational activity will allow participants to:

  • Review available evidence for the use of checkpoint inhibitors and novel agents, including antibody drug conjugates and fibroblast growth factor receptor (FGFR) inhibitors.
  • Explore strategies for identification and management of immune-related and FGFR inhibitor-associated adverse events.
  • Outline effective solutions for improving coordination and communication within the multidisciplinary cancer care team to improve patient outcomes.

Credits Available: 0.75 AMA PRA Category 1 Credit(s)™; 0.75 contact hour for nurses.
Enroll Today

 

Emerging Therapies for the Management of Castration-Sensitive Prostate Cancer

This education activity will provide guidance on the optimal management of mCSPC to oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The educational program will address some of the challenges in optimal sequencing of care in mCSPC and will provide an opportunity to discuss with leading oncology experts and colleagues how new research clinical updates can be translated into new patient care strategies.

Speakers:

  • Archana Ajmera, MSN, ANP-BC-AOCNP, Advanced Practice Provider Supervisor, Division of Hematology/Oncology, UCSD Moores Cancer Center
  • Pedro C. Barata, MD, MSC, Assistant Professor, Deming Department of Medicine Division of Hematology/Oncology, Genitourinary Cancers Tulane University, Tulane University, New Orleans, LA

Credits Available: 1.0 AMA PRA Category 1 Credit(s)™: 1.0 contact hour of continuing pharmacy education credit; 1.0 contact hour for nurses.

Enroll Today

 

Oral Agents for Advanced Hormone Receptor Positive Breast Cancer

Improve your knowledge of, confidence, and competence in the appropriate use of oral agents for patients with HR-positive, advanced, or metastatic breast cancer during the HOPA Satellite Symposium Pre-Conference, Oral Agents for Advanced Hormone Receptor Positive Breast Cancer, April 12 at 1:00 PM CDT. Hear from panelists as they discuss challenging cases of patients, their guidance on evidence-based treatment choices for patients in the various lines of treatment, and the management of treatment-related severe adverse events in these patients.

Walk away with strategies to manage acquisition of, adherence to, and treatment-related adverse events of oral drug-inclusive treatment regimens as part of a multidisciplinary team.

Credits Available: 1.0 AMA PRA Category 1 Credit(s)™: 1.0 contact hour for nurses; 1.0 contact hour of continuing pharmacy education credit when the course is taken through the HOPA learning portal.
Enroll Today
To claim continuing pharmacy education credit, enroll here.